A dye that had to be purer than anything on the market
European manufacturer of analytical equipment for dairy testing
Stable supply · 100 mg → 2-3 kg per year · 0.5-1 kg per delivery
Point Zero. The dye was available only from Asian sources at around 60 % content. At that purity it was unusable in a diagnostic instrument, and no supplier offered better.
Our contribution. The synthesis and the purification process - developed in-house rather than re-sourced, then made repeatable at kilogram scale.
Evidence. Above 99.5 % purity. From first 100 mg to 2-3 kg per year.
Status. Orders three to four times a year, without interruption since 2019.
Anonymised project · 02
Ultra-high-purity polyaromatics, with the IP staying in one legal field
European specialty chemicals company serving the consumer electronics industry
Scale-up · 50-100 g per compound
Point Zero. A family of polysubstituted polyaromatic amines at a purity target of 99.8 % - high enough that purification, not synthesis, decided the project. The partner also required the work to remain inside a single European legal field.
Our contribution. Route, purity and the jurisdictional constraint together.
Evidence. Products delivered at the target specification.
Status. An ongoing programme. Working together since 2022.
Anonymised project · 03
A labelling methodology built to survive scale-up
European chemical concern
Scale-up · 20-100 g
Point Zero. The partner did not need the compounds so much as a method: isotopic labelling that would still work when the scale went up. Nobody knew whether it would - that was the interesting part.
Our contribution. Development of the full labelling methodology, designed from the outset for later scale-up rather than for one successful batch.
Evidence. Labelling level above 90 % against a 99 % target.
Status.Working together since 2022.
Anonymised project · 04
From racemic to chiral, and it had to scale
European producer of crop protection products
Trial → scale-up · mg → kg
Point Zero. A small molecule intended to replace one already used in the agrochemical industry. It had to be made as a single enantiomer, and it had to scale.
Our contribution. Synthesis development from racemic to chiral, with scalability designed in from the first route. Twenty-four months of combined FTE and custom-order work.
Evidence.Patent issued.
Status. The compound moved into the partner's own programme.
Anonymised project · 05
A stereoselective route
that did not exist yet
Pharmaceutical company, US
Trial → scale-up · mg → kg
Point Zero. A library of chiral compounds for an antiviral programme, five to ten steps each. The biology could not begin until the material existed.
Our contribution. Stereoselective synthesis developed from scratch, then delivery of the library at the scale the testing required.
Evidence. Delivered over twelve months.
Anonymised project · 06
Compounds nobody had made, because nobody had designed them
European biotechnology company
Trial → repeat orders · 1-5 g
Point Zero. Lipids designed by the partner's own team for gene-delivery research - five to ten steps, with no literature to fall back on, because the compounds did not exist.
Our contribution. Synthesis and purification developed together, for each new design in the series.
Evidence. 1-5 g per order, across successive designs.
Status. Orders once or twice a year. Working together since 2020.
Anonymised project · 07
Impurity identification and isolation for analytical method validation
European pharmaceutical company
Trial → repeat orders · 5-10 g
Point Zero. Impurities identified during development, each needing to exist as a reference standard before the analytical method could be validated. Three to six steps each.
Our contribution. Custom synthesis and purification of every impurity, to reference-standard quality.
Evidence. 5-10 g per compound, delivered with full analytical documentation.
Status. Recurring orders, one to two times a year.
Anonymised project · 08
From ten grams to twenty kilograms, same team
European pharmaceutical company
Trial → scale-up · 5-10 g → 10-20 kg
Point Zero. Newly identified targets for neurodegenerative research - needed first in gram quantities, then, once the programme advanced, at a scale a laboratory batch cannot reach.
Our contribution. Custom synthesis of each target, then scale-up development, without changing the team or technical responsibility.
Evidence. 5-10 g, then scale-up to 10-20 kg.
Status. Short projects three to four times a year. Working together since 2019.
Anonymised project · 09
A scalable route, developed before anyone knew one existed
US technology company
Scale-up → stable supply · up to 5 kg
Point Zero. Intermediates for materials production, with no scalable and affordable method in place - and no certainty that one could be found.
Our contribution. Developing the scalable route before there was a guarantee it existed, and pricing that uncertainty openly rather than hiding it in a schedule.
Evidence. Quantities up to 5 kg, followed by ongoing supply.
Status. Stable ongoing supply.
Anonymised project · 10
Polymer materials for energy technology
European energy and technology company
Scale-up · up to 10 kg
Project scope. Polymer materials for energy technology.
Evidence. Quantities up to 10 kg.
next step
Tell us what you need to make or achieve.
Share a target structure or describe your goal. A chemist will help define the next step.
